Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More Press Releases

Energy and technology companies lead US stocks higher

Jan 22, 2018

NEW YORK — Energy and technology companies are advancing Monday as U.S. stocks continue to rise, and smaller companies are also making gains after the Senate reached a short-term deal to end the government shutdown. High-dividend stocks are also higher as bond yields decline, but industrial companies are falling. Yields had climbed to their highest level in more than three years last week. KEEPING SCORE: The Standard & Poor's 500 index picked up 14 points, or 0.5 percent, to 2,825 as of 12:45 p.m. Eastern time after closing at another all-time high on Friday. The Dow Jones industrial average rose...

Global stocks mixed after US government shutdown

Jan 22, 2018

BEIJING — Global stocks were mixed Monday after global investors shrugged off the latest U.S. government shutdown. KEEPING SCORE: In early trading, German's DAX was off 8 points at 13,423.85 and France's CAC 40 declined 0.1 percent to 5,519.85. London's FTSE 100 was up 5 points at 7,735.77. On Friday, the DAX rose 1.2 percent, the CAC 40 added 0.6 percent and the FTSE 100 gained 0.4 percent. On Wall Street, the future for the Dow Jones industrial average was off 0.2 percent and that for the Standard & Poor's 500 index was down 0.1 percent. ASIA'S DAY: The Shanghai...

Long shutdown could hurt economy, a short one just 'a blip'

Jan 22, 2018

If the shutdown lasts just days or even a couple of weeks, the robust stock market that President Donald Trump has boasted about probably will emerge unscathed. A longer impasse, economists say, could rattle consumer and investor confidence, pulling stocks lower and dragging down the economy. Economists and investment advisers interviewed by The Associated Press generally didn't foresee the shutdown that began Saturday lasting long enough to stifle the economy much. With pivotal elections in November, both parties would want to shield voters from any pain. Investors and consumers are feeling optimistic now based on the tax cut signed into...

Puerto Rico finances under scrutiny amid plea for help

Jan 22, 2018

SAN JUAN, Puerto Rico — Top financial officials in Puerto Rico offered a peek Friday into why the U.S. territory is mired in an 11-year recession as a federal control board demanded more transparency and information about the island's finances. Officials said that for decades, the number of government bank accounts was unclear, public agencies used one of four different accounting systems, and government vendors charged more for services when not paid, among other issues. The testimony they provided during a public hearing held by the board comes as Puerto Rico's government continues to insist that it is running out...

Stocks rise despite looming US government closure

Jan 22, 2018

HONG KONG — Stock markets rose Friday as investors looked past the threat of a U.S. federal government shutdown and focused on a strong underlying economy. The price of oil fell on a report saying U.S. production is set to rise further above 50-year highs. KEEPING SCORE: Germany's DAX was up 1.1 percent to 13,424 and France's CAC 40 rose 0.5 percent to 5,521. Britain's FTSE 100 gained a more modest 0.3 percent to 7,720 after data showed retail sales fell sharply in the holiday spending month of December. Wall Street was poised to open higher: Dow futures added 0.3...

Subscribe to our newsletter!

Your Name

Your Email Address